Chronic obstructive pulmonary disease (COPD) is underdiagnosed and undertreated in São Paulo (Brazil). Results of the PLATINO Study

Abstract

Chronic obstructive pulmonary disease (COPD) is a common disease in adults over 40 years of age and has a great social and economic impact. It remains little recognized and undertreated even in developed countries. However, there are no data about its diagnosis and treatment in Brazil. The objectives of the present study were to evaluate the proportion of COPD patients who had never been diagnosed and to determine if the COPD patients who had been identified were receiving appropriate treatment. The Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) was a randomized epidemiological study of adults over 40 years living in five metropolitan areas, including São Paulo. The studied sample was randomly selected from the population after a division of the metropolitan area of São Paulo in clusters according to social characteristics. All subjects answered a standardized questionnaire on respiratory symptoms, history of smoking, previous diagnosis of lung disease, and treatments. All subjects performed spirometry. The criterion for the diagnosis of COPD was defined by a post-bronchodilator FEV$_1$/FVC ratio lower than 0.7. A total of 918 subjects were evaluated and 144 (15.8%) met the diagnostic criterion for COPD. However, 126 individuals (87.5%) had never been diagnosed. This undiagnosed group of COPD patients had a lower proportion of subjects with respiratory symptoms than the previously diagnosed patients (88.9 vs 54.8%) and showed better lung function with greater FEV$_1$ (86.8 ± 20.8 vs 68.5 ± 23.6% predicted) and FVC (106.6 ± 22.4 vs 92.0 ± 24.1% predicted). Among the COPD patients, only 57.3% were advised to stop smoking and 30.6% received the influenza vaccine. In addition, 82.3% did not receive any pharmacological treatment. In conclusion, COPD is underdiagnosed and a large number of COPD patients are not treated appropriately.

Key words
- Chronic obstructive pulmonary disease
- Diagnosis
- Treatment
- Vaccination
- Smoking
- Latin American Project for the Investigation of Obstructive Lung Disease
Introduction

Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by chronic airflow obstruction, which is not totally reversible, is generally progressive and is associated with an abnormal inflammatory response of the lungs to the inhalation of particles and toxic gases (1). COPD includes two entities, i.e., chronic bronchitis and emphysema. A diagnosis should be considered in any individual over 40 years old presenting respiratory symptoms and/or a history of exposure to risk factors, particularly smoking. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, COPD diagnosis is based on a post-bronchodilator forced expiratory volume in 1 s (FEV₁) over forced vital capacity (FEV₁/FVC) ratio lower than 0.7 (1).

Until the recent publication of data from the PLATINO Study (Latin American Project for the Investigation of Obstructive Lung Disease; 2,3), the only population study on the prevalence of chronic bronchitis in Brazil was performed in Pelotas (RS) and was based only on respiratory symptoms. The prevalence of chronic bronchitis was 12.7% (4). The PLATINO Study was performed in order to assess COPD prevalence by means of home spirometry in individuals over 40 years of age living in five large metropolitan areas in Latin America (São Paulo, Montevideo, Santiago, Caracas, and Mexico City). In Brazil, COPD prevalence was 15.8% (95%CI = 13.5-18.1), according to a post-bronchodilator FEV₁/FVC ratio lower than 0.7. Apart from its high prevalence, COPD is a disease of great social and economic impact (5). In 2005, more than 174,000 patients were admitted to hospitals covered by the Unified Health System (Sistema Único de Saúde) and diagnosed as having COPD, with the disease resulting in over 30,000 deaths (6).

COPD is underestimated and underdiagnosed globally (7,8), but no statistics about the disease are available for Brazil. Since COPD has a high social and economic impact, the information regarding the undiagnosed proportion of these patients may produce data to be used by health authorities in our country to improve COPD management. COPD therapy has been well-established and is divided into pharmacological and non-pharmacological treatments (1,9,10). Pharmacological treatment includes the use of inhalatory bronchodilators and corticosteroids, stratified according to the stage of the disease, as determined by FEV₁. Among non-pharmacological treatments, the two most important measures are smoking cessation and vaccination against influenza. However, it is not known how these guidelines are followed in Brazil. The objectives of the present study were to evaluate the proportion of undiagnosed COPD patients among São Paulo PLATINO Study patients, and to evaluate their pharmacological and non-pharmacological treatment.

Material and Methods

Study design

The study was approved by the Ethics and Research Committee of Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil, and was based on data collected by the PLATINO Study. Methods and results on COPD prevalence in Latin America have been previously published (2,3). The PLATINO Study was a transverse study undertaken in order to evaluate COPD prevalence and risk factors in five large metropolitan areas of Latin America, and the São Paulo metropolitan area was chosen in Brazil. The sample studied was selected in several stages. The metropolitan area was first stratified into the main city and surrounding municipalities. These two subsets were further stratified by socioeconomic status. We selected 68 census tracts at each site, taking stratification into account and using a prob-
ability of selection proportional to the number of households in each tract. Within each tract, we counted the number of people in each household and every count was updated from the most recent census. We chose an average of 15 households using systematic sampling within each tract. All adults aged 40 years or more living in the selected households were invited to participate and were submitted to the evaluations in their own homes after signing an informed consent form to participate in the study. Sample size calculations suggested that 800 people would be needed in each area to estimate a prevalence of up to 30% with a margin of error of less than 4 percentage points. We aimed to locate about 1020 eligible participants per site, with a predicted 20% refusal rate.

All interviews and examinations took place at home, and proxy information was not accepted. We obtained data about several factors potentially associated with COPD using a questionnaire that included sections of the American Thoracic Society Division of Lung Diseases (ATS/DLD) (11), European Community Respiratory Health Survey II (12), and Lung Health Study (13) instruments. Questions were related to respiratory symptoms, previous diagnosis of pulmonary diseases, influenza vaccination within the previous year, educational information on smoking cessation, and previous pharmacological treatments. We measured height with a portable stadiometer (Seca®, Curitiba, PR, Brazil; precision 0.1 cm). Weight was measured with an electronic scale (Tanita®, Curitiba, PR, Brazil; precision 200 g). Pre- and post-bronchodilator spirometry was performed (Easy-One®, NDD Medical Technologies, Chelmsford, MA, USA, and Zurich, Switzerland).

**Diagnosis of chronic obstructive pulmonary disease**

COPD diagnosis was based on a post-bronchodilator FEV₁/FVC ratio lower than 0.7 and COPD stage was determined using the most recent version of the GOLD guidelines (14).

**Definition of previous diagnosis of pulmonary emphysema, chronic bronchitis and COPD**

The three principal questions that identified a previous diagnosis of pulmonary emphysema, chronic bronchitis and COPD were: 1) “Has your health provider told you that you have lung emphysema?”; 2) “Has your health provider told you that you have chronic bronchitis?”, and 3) “Has your health provider told you that you have chronic obstructive pulmonary disease (COPD)?”. The absence of a previous diagnosis of emphysema, chronic bronchitis and COPD was considered wherever the subject answered “no” to any of these questions and presented an FEV₁/FVC ratio lower than 0.7 as assessed by spirometry.

**Evaluation of non-pharmacological treatment of COPD**

Smoking cessation and influenza vaccination were determined by means of the following questions: 1) “Has your health provider at any time advised you to stop smoking?”, and 2) “Have you taken the influenza vaccination within the last 12 months?”.

**Evaluation of pharmacological treatment of COPD**

Pharmacological treatment was defined as active when the answer to the question “Have you taken any lung or breathing medication within the last 12 months?” was “yes”.

**Statistical analysis**

The group of COPD patients was divided into two subgroups: those previously diag-
nosed as having COPD and those undiagnosed. The two groups were comparable in terms of demographic data and use of pharmacological and non-pharmacological treatment. The numerical data in the descriptive analysis are reported as means ± SD. Categorical variables are presented as absolute numbers and as a percentage of the total. FEV₁ and FVC are reported as percentages of predicted values for age and height. COPD patients were stratified into stages I, II, III, and IV according to disease severity based on GOLD guidelines. For statistical analysis, stages III and IV were grouped together. The mean values of the numerical variables were compared between groups by the Student t-test. Comparison of the proportion of the categorical variables between independent groups was performed by the chi-square test. The level of significance was set at P < 0.05 in all analyses.

Results

A total of 984 individuals were interviewed. However, 21 refused to perform the spirometry test, and 45 individuals did not perform the post-bronchodilator spirometry. Thus, a total sample of 918 individuals was submitted to pre- and post-bronchodilator spirometry. Of these 918 individuals, 144 (15.8%) presented an FEV₁/FVC ratio lower than 0.7 and were characterized as COPD patients. The demographic data of these COPD patients are presented in Table 1.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Schooling (years)</th>
<th>Skin color</th>
<th>Smoking status</th>
<th>Smoking consumption (packs/year)</th>
<th>Spirometry</th>
<th>COPD stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male 73 (50.7%)</td>
<td>59.7 ± 11.6</td>
<td>5.9 ± 4.7</td>
<td>Caucasian 85 (59.0%)</td>
<td>Current smoker 51 (35.4%)</td>
<td>18.9 ± 23.5</td>
<td>FEV₁/FVC 0.62 ± 0.09</td>
<td>Stage I 90 (62.5%)</td>
</tr>
<tr>
<td></td>
<td>Female 71 (49.3%)</td>
<td></td>
<td></td>
<td>Non-Caucasian 59 (41.0%)</td>
<td>Former smoker 45 (31.3%)</td>
<td></td>
<td>FVC (% predicted) 104.7 ± 23.1</td>
<td>Stage II 43 (29.9%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non-smoker 48 (33.3%)</td>
<td></td>
<td>FEV₁ (% predicted) 84.5 ± 21.9</td>
<td>Stages III and IV 11 (7.6%)</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD or number of subjects with percent in parentheses. COPD = chronic obstructive pulmonary disease; FEV₁ = forced expiratory volume in 1 s; FVC = forced vital capacity.

Evaluation of a previous diagnosis of lung emphysema, chronic bronchitis and COPD

Only 3 of the COPD patients studied (2.1%) had received a previous diagnosis of lung emphysema, 15 (10.4%) had received a diagnosis of chronic bronchitis and 3 (2.1%) a diagnosis of COPD. When the three diagnoses were grouped, only 18 individuals (12.5%) had been previously diagnosed as COPD patients (Table 2). When lung function was compared between the previously
diagnosed COPD and undiagnosed COPD groups, the latter was found to present a higher FEV<sub>1</sub>/FVC ratio (0.62 ± 0.08 vs 0.57 ± 0.12), higher FEV<sub>1</sub> (86.8 ± 20.8 vs 68.5 ± 23.6% predicted) and FVC (106.6 ± 22.4 vs 92.0 ± 24.1% predicted), which indicate better lung function. Individuals in stages I and II comprised the largest percentage of undiagnosed individuals, 92.2 and 86.0%, respectively, while individuals in stages III and IV presented a smaller proportion of undiagnosed individuals (54.5%), with a statistically significant difference between them (Table 2). Variables such as gender, age, schooling, race, marital status, and smoking consumption were not statistically different between the two groups. However, when respiratory symptoms were evaluated, it was observed that the previously diagnosed COPD group presented a greater proportion of patients with respiratory symptoms in comparison with the undiagnosed group: chronic cough (44.4 vs 9.5%), dyspnea (72.2 vs 34.9%), wheezing (77.8 vs 34.9%), and a combination of any symptoms (88.9 vs 54.8%), all of them with statistically significant differences (Figure 1). There was no statistically significant difference in expectoration between the two groups. Other characteristics such as gender, age, schooling, skin color, smoking status, and smoking consumption did not differ between groups (Table 2).

**Evaluation of non-pharmacological treatment**

Of the 96 smokers or former smokers in the group of COPD patients, only 55 (57.3%) had been advised to stop smoking. When the groups of previously diagnosed and undiagnosed individuals were compared, no statistical difference was observed (Table 3). When COPD patients were asked about influenza vaccination during the previous year, only 44 individuals (30.6%) reported that they had been immunized. No significant difference was observed between previously

---

**Table 2. Comparison of the demographic data between subjects with and without a diagnosis of chronic obstructive pulmonary disease (COPD).**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Previously diagnosed COPD group</th>
<th>Undiagnosed COPD group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>18 (12.5%)</td>
<td>126 (87.5%)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7 (38.9)</td>
<td>66 (52.4)</td>
</tr>
<tr>
<td>Female</td>
<td>11 (61.1)</td>
<td>60 (47.6)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.5 ± 14.0</td>
<td>59.6 ± 11.3</td>
</tr>
<tr>
<td>Schooling (years)</td>
<td>3.7 ± 3.4</td>
<td>5.2 ± 5.2</td>
</tr>
<tr>
<td>Skin color</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>9 (50.0%)</td>
<td>76 (60.3%)</td>
</tr>
<tr>
<td>Non-Caucasian</td>
<td>9 (50.0%)</td>
<td>50 (39.7%)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>4 (22.2%)</td>
<td>47 (37.3%)</td>
</tr>
<tr>
<td>Former smoker</td>
<td>6 (33.3%)</td>
<td>39 (31.0%)</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>8 (44.5%)</td>
<td>40 (31.7%)</td>
</tr>
<tr>
<td>Smoking consumption (packs/year)</td>
<td>14.3 ± 21.3</td>
<td>19.6 ± 23.8</td>
</tr>
<tr>
<td>Spirometry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt;/FVC</td>
<td>0.57 ± 0.12</td>
<td>0.62 ± 0.08*</td>
</tr>
<tr>
<td>FVC (% predicted)</td>
<td>92.0 ± 24.1</td>
<td>106.6 ± 22.4*</td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; (% predicted)</td>
<td>68.5 ± 23.6</td>
<td>86.8 ± 20.8*</td>
</tr>
<tr>
<td>COPD stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>7 (7.8%)</td>
<td>83 (92.2%)*</td>
</tr>
<tr>
<td>Stage II</td>
<td>6 (13.9%)</td>
<td>37 (86.1%)</td>
</tr>
<tr>
<td>Stages III and IV</td>
<td>5 (45.5%)</td>
<td>6 (54.5%)</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD or number of subjects with percent in parentheses. For abbreviations, see legend to Table 1.

*P < 0.05 compared to previously diagnosed COPD group (Student t-test or chi-square test).

**Figure 1. Comparison of the occurrence of symptoms between the group with a previous diagnosis of chronic obstructive pulmonary disease (COPD; open columns) and undiagnosed COPD subjects (filled columns). NS = non-significant (chi-square test).**
diagnosed and undiagnosed individuals (Table 3).

Evaluation of pharmacological treatment

When individuals were questioned about the use of lung medication within the previous 12 months, only 24 in the group of COPD patients (16.7%) reported that they had received medication (Table 3). Concerning the whole group of COPD patients, 82 individuals in stage I (91.2%), 32 in stage II (74.4%) and 6 in stages III and IV (54.5%) had not received any medication within the previous year. Among the previously diagnosed COPD group, only nine had used medication within the previous year (50%). On the other hand, in the undiagnosed COPD groups only 15 individuals (11.9%) had received treatment, with a statistically significant difference (P = 0.001).

Discussion

As far as we know, this is the first study performed in Brazil in order to assess previous diagnosis and therapeutic approach to COPD patients. These results came from the PLATINO Study, which was the first population-based study on the prevalence and impact of COPD in large metropolitan regions of five countries of Latin America (2,3).

Due to the high mortality and the high cost of COPD management and treatment in its most advanced stages, early identification of COPD and appropriate treatment are of the utmost importance to prevent these stages from being reached. It has been reported that the absence of diagnosis of airflow limitation is very common in the general population (15). In the present study, 87.5% of the individuals diagnosed with COPD by the PLATINO Study indicated that they had never been diagnosed previously. However, the low proportion of undiagnosed individuals is not exclusive to Brazil, with a 40% rate in Sweden (16) and a 78.2% rate in Spain (17). In the present study, we observed that undiagnosed COPD patients presented better lung function and fewer respiratory symptoms (chronic cough, dyspnea and wheezing). These data are in accordance with those of other studies. In a Dutch study, it was reported that the absence of diagnosis was associated with a lower smoking load, absence of dyspnea and expectoration (18). On the other hand, a history of smoking and wheezing may be a good predictor of airflow obstruction (19).

As far as we know, this is the first study performed in Brazil in order to assess previous diagnosis and therapeutic approach to COPD patients. These results came from the PLATINO Study, which was the first population-based study on the prevalence and impact of COPD in large metropolitan regions of five countries of Latin America (2,3). The Table 3. Proportion of subjects with and without a previous diagnosis of chronic obstructive pulmonary disease (COPD) who received non-pharmacological or pharmacological treatment.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>All COPD subjects</th>
<th>Previously diagnosed COPD group</th>
<th>Undiagnosed COPD group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation</td>
<td>55 (57.3%)</td>
<td>7 (70.0%)</td>
<td>48 (55.8%)</td>
</tr>
<tr>
<td>Influenza vaccination</td>
<td>44 (30.6%)</td>
<td>6 (33.3%)</td>
<td>38 (30.2%)</td>
</tr>
<tr>
<td>Pharmacological treatment</td>
<td>24 (16.7%)</td>
<td>9 (50.0%)</td>
<td>15 (11.9%)*</td>
</tr>
</tbody>
</table>

Data are reported as means ± SD or number of subjects with percent in parentheses. *P < 0.001 compared to the previously diagnosed COPD group (chi-square test).
When COPD patients stop smoking there may be a reduction in the decline of lung function (27). The proportion of smoking COPD patients who had received any advice on smoking cessation was low (57.3%), lower than rates observed in two international studies, where it was approximately 70% (28,29). However, the design of these two studies differed from that of the PLATINO Study: one of them evaluated patients who were admitted to hospitals due to COPD exacerbation (28) and the other evaluated primary health care services (29). Thus, the PLATINO Study results reflect the actual approach to COPD patients in the community and show that advice on smoking cessation should be more widespread in our country.

Vaccination against influenza may reduce morbidity and mortality in COPD patients (30) and should be administered to everyone with the disease, regardless of age. A Spanish study showed that of the individuals who were admitted to hospitals due to COPD exacerbation, 28% had not been vaccinated against influenza (31); a similar finding was also reported in the United States (32).

Our results showed that 83.3% of the COPD patients had not been receiving any pharmacological treatment over the last year. In Spain, it was reported that only 19.3% of COPD patients were receiving any drug treatment. In addition, less than half of the severe and very severe cases (FEV₁ <50%) were receiving any treatment for respiratory disease (17). The recommendations for pharmacological treatment are not dependent on the presence of symptoms. All moderate, severe and very severe patients (FEV₁ less than 80%) according to the Brazilian Consensus in COPD (10), GOLD (14) or ATS/ERS Guidelines (9) are advised to receive pharmacological treatment continuously. This situation was also common in other studies performed in Europe. In a British study, it was shown that only 36.9% of the individuals affected by respiratory diseases (asthma or COPD) used bronchodilators or inhalatory corticosteroids (33). These data show that the low rate of COPD patients under treatment is not an exclusive feature of Brazil. Our study has demonstrated that COPD patients do not usually receive the recommended pharmacological and non-pharmacological treatments. The most plausible reason for this may be related to the absence of a COPD diagnosis, as shown in the previously diagnosed COPD group which presented a higher proportion of subjects receiving pharmacological treatment (Table 3). If the patients have not been diagnosed, they will not be treated. In addition, the underdiagnosed group presented a smaller proportion of respiratory symptoms, which may have been responsible for the underdiagnosis of the disease. Consequently, if the patients have fewer symptoms they will be less diagnosed and less treated. On the other hand, the patients were asked if they had used any medication over the previous year and not if these medications had been prescribed by a physician. So, it was impossible to know if medication was prescribed and had not been taken by the patient. Self-medication is a common practice in Brazil, which makes it impossible to know, with the tools used in this study, at what point there was failure of the pharmacological treatment.

The main limitation of the present study is the spirometry criterion for COPD diagnosis, since severe asthmatic individuals and those over 70 years of age may present an FEV₁/FVC ratio lower than 0.7. However, it is not possible to differentiate asthma and COPD in an individual over 40 years old by spirometry alone (34-36), although the use of the post-bronchodilator spirometry value is supposed to reduce the false-positive cases. However, the spirometry criterion adopted in our study is the one most commonly described in the COPD documents (9,10) and used in epidemiological studies (37-39) and allows us to compare our results to those of
other studies. These patients were not excluded from the sample because, for COPD epidemiological studies, the international criterion for a diagnosis of COPD is a post-bronchodilator FEV₁/FVC ratio lower than 0.7 (9,10,14). The adoption of this criterion definitely involves the risk of including asthmatics or normal aged people. However, we should point out that spirometry was performed after the inhalation of a bronchodilator, which is the routine test used to exclude all mild and moderate asthmatics. Besides, it is a consensus that the final individual diagnosis of asthma should always be made on a clinical basis. This fixed ratio criterion should be seen as a tool for population screening. This diagnostic criterion is recommended by the GOLD guidelines and has become the most widely used one due to its feasibility and better capacity for increasing the diagnosis of COPD.

This study demonstrated that COPD is underdiagnosed and undertreated in Brazil. These facts can generate higher impact to COPD patients such as higher morbidity and mortality and higher lung function decline. A better screening program is needed to improve the treatment of these patients and to reduce the impact of the disease in their lives.

References


23. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Longitudinal methods for describing the relationship between pulmonary function, respiratory symptoms and smoking in elderly subjects: the


